Pegozafermin, a fibroblast growth factor FGF21 analog, is an endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. It reduces triglyceride (TG) levels and is used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) [1] [2].

Pegozafermin consistently and significantly reduces triglycerides (TG) levels while improving hepatic fat and glycemic control, which is important as high TG levels can lead to organ failure, cardiovascular disease, and acute pancreatitis [1, 2].